Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Urothelial Carcinoma
NCT04879329Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 12
01
Overview
A Phase 2 trial of disitamab vedotin in urothelial carcinoma (UC), sponsored by Pfizer. Started May 2022; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04879329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04879329.